Inclusion Criteria:  Patients aged 1 to < 18 years Patients with cytologically confirmed and documented newly diagnosed ALL according to National Comprehensive Cancer Network guidelines 2020 (see Appendix 2), excluding B-cell Burkitt ALL Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2 (see Appendix 3) Highly effective contraception method Signed informed consent and assent, when appropriate  Non-inclusion Criteria:  Unlikely to cooperate in the study Pregnant and lactating women Participation in another interventional study at the same time; participation in non-interventional registries or epidemiological studies is allowed Participant already enrolled in the study (informed consent signed) Women of childbearing potential tested positive in a serum pregnancy test within 7 days prior to the treatment period Inadequate hepatic function (bilirubin > 1.5 times upper limit of normal (ULN), transaminases > 5x ULN) Inadequate renal function defined as serum creatinine > 1.5 x ULN Prior treatment with chemotherapy or radiotherapy (except steroids and intrathecal therapy) Prior surgery or bone marrow transplant related to the studied disease Down Syndrome Psychiatric illness/social situation that would limit compliance with study requirements Known history of pancreatitis Known history of significant liver disease Known carriers of HIV antibodies Significant laboratory abnormality likely to jeopardize the patients' safety or to interfere with the conduct of the study, in the investigator's opinion Pre-existing known coagulopathy (e.g. haemophilia and known protein S deficiency) History of previous or concurrent malignancy History of sensitivity to polyethylene glycol (PEG) or PEG-based drugs Severe or uncontrolled active acute or chronic infection Uncontrolled intercurrent illness including life-threatening acute tumor lysis syndrome (e.g. with renal failure), symptomatic congestive heart failure, cardiac arrhythmia